Citryll’s shareholders are the founders, Dutch venture capitalists BOM and Curie Capital, Brightgene (represented by Laurel Venture), a Chinese biotech funded by among others Sequoia China and Highlight Capital. For the second round of its series A there is an opportunity for additional investors to join the current syndicate. Parties interested to learn more, please contact us directly. Citryll is also interested in patient foundations interested in investing in the advancement of Citryll’s programme and bringing it to patients, either through grants, equity or loans.